prof. dr. W. (Wijnand) Helfrich

Faculteit Medische Wetenschappen/UMCG

Telefoon:

050 361 3733

E-mail:

w.helfrich umcg.nl

Homepage ORCID Research Portal

Publicaties

Enhancing the Anticancer Activity of a Carcinoma-Directed Peptide-HLA-I Fusion Protein by Armoring with Mutein IFNα

Samplonius, D. F., van Wijngaarden, A. P., Koll, L., Ke, X. & Helfrich, W., 29-mrt.-2025, In: International Journal of Molecular Sciences. 26, 7, 19 blz., 3178.

Onderzoeksoutput › › peer review

Extracellular Vesicles in Cancer Immunotherapy

Ke, X., Helfrich, W. & Zhang, H., 1-jan.-2024, Extracellular Vesicles: From Bench to Bedside. Wang, Q. & Zheng, L. (uitgave). Springer Nature, blz. 467-474 8 blz.

Onderzoeksoutput: Chapter › › peer review

Visible Light Control over the Cytolytic Activity of a Toxic Pore-Forming Protein

Volarić, J., van der Heide, N. J., Mutter, N. L., Samplonius, D. F., Helfrich, W., Maglia, G., Szymanski, W. & Feringa, B. L., 16-feb.-2024, In: ACS chemical biology. 19, 2, blz. 451–461 11 blz., 3c00640.

Onderzoeksoutput › › peer review

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

Ploeg, E. M., Britsch, I., van Wijngaarden, A. P., Ke, X., Hendriks, M. A. J. M., Samplonius, D. F. & Helfrich, W., jul.-2023, In: Cancers. 15, 14, 15 blz., 3651.

Onderzoeksoutput › › peer review

Applications of Anti-Cytomegalovirus T Cells for Cancer (Immuno)Therapy

Britsch, I., van Wijngaarden, A. P. & Helfrich, W., aug.-2023, In: Cancers. 15, 15, 22 blz., 3767.

Onderzoeksoutput › peer review

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR

Ploeg, E. M., Samplonius, D. F., Xiong, X., Ke, X., Hendriks, M. A. J. M., Britsch, I., Van Wijngaarden, A. P., Zhang, H. & Helfrich, W., 21-sep.-2023, In: Journal for immunotherapy of cancer. 11, 9, 15 blz., e006837.

Onderzoeksoutput › › peer review

Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells

Britsch, I., van Wijngaarden, A. P., Ke, X., Hendriks, M. A. J. M., Samplonius, D. F., Ploeg, E. M. & Helfrich, W., 2023, In: OncoImmunology. 12, 1, 2207868.

Onderzoeksoutput › › peer review

A proof-of-concept study on the use of a fluorescein-based 18F-tracer for pretargeted PET

Helbert, H., Ploeg, E. M., Samplonius, D. F., Blok, S. N., Antunes, I. F., Böhmer, V. I., Luurtsema, G., Dierckx, R. A. J. O., Feringa, B. L., Elsinga, P. H., Szymanski, W. & Helfrich, W., 3-mrt.-2022, In: EJNMMI Radiopharmacy and Chemistry. 7, 1, 11 blz., 3.

Onderzoeksoutput › › peer review

Impact of cumulative complications on 1-year treatment-related healthcare costs in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

van der Zant, F. A., Kooijman, B. J. L., Hentzen, J. E. K. R., Helfrich, W., Ploeg, E. M., van Ginkel, R. J., van Leeuwen, B. L., Been, L. B., Klaase, J. M., Hemmer, P. H. J., van der Hilst, C. S. & Kruijff, S., 2-sep.-2022, In: BJS open. 6, 5, 9 blz., zrac109.

Onderzoeksoutput › › peer review

Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles

Xiong, X., Ke, X., Wang, L., Lin, Y., Wang, S., Yao, Z., Li, K., Luo, Y., Liu, F., Pan, Y., Yeung, S.-C. J., Helfrich, W. & Zhang, H., 2022, In: Journal of Extracellular Vesicles. 11, 8, 19 blz., e12243.

Onderzoeksoutput › › peer review